PharmAla's Strategic Agreement for MDMA Supply
PharmAla Biotech Holdings Inc. is making headlines with its latest agreement to supply LaNeo™ MDMA for a clinical trial. In exchange for this product, the company will receive a full and perpetual license to all efficacy and safety data generated in the trial. This innovative collaboration reflects PharmAla's commitment to the advancement of MDMA-related research and its dedication to improving therapeutic options in this arena.
The CEO's Vision
According to Nicholas Kadysh, the CEO of PharmAla, having a robust product lays the groundwork for unique opportunities. He emphasized that while the majority of their LaNeo MDMA transactions operate on commercial terms, there are circumstances where they opt for discounts in return for valuable intellectual property. This strategic maneuver showcases the company's adaptability in the ever-evolving biotech landscape.
Details of the Agreement
The company aims to conclude the licensing and data sharing agreement by the end of the current calendar year. At present, the identities of the Principal Investigators and the research institution involved remain undisclosed, pending the execution of a binding agreement. This allows PharmAla to maintain a level of confidentiality until all aspects are finalized.
Research Access and Support
Researchers interested in working with LaNeo MDMA can access comprehensive quality information through a dedicated tool. PharmAla is poised to provide research customers with swift support to facilitate the transition of their clinical trial registrations and IRB approvals into the LaNeo MDMA Chemistry, Manufacturing, and Control package. This commitment to supporting researchers underscores PharmAla's pivotal role in advancing clinical trials in MDMA therapy.
Incentives for Data Sharing
PharmAla is open to offering discounts for data sharing under suitable circumstances. Qualified researchers who wish to explore these opportunities can reach out directly to the company. Their proactive approach could pave the way for meaningful collaborations that benefit both the research community and PharmAla.
Debt Settlement Through Share Issuance
In addition to the recent agreement, PharmAla has taken steps to strengthen its financial position by settling $100,000 owed to an arm’s length creditor through the issuance of 459,770 common shares, priced at a deemed value of $0.2175 per share. This move reflects the company's strategic focus on maintaining a healthy balance sheet while investing in growth and innovation.
About PharmAla Biotech Holdings Inc.
PharmAla Biotech Holdings Inc. is recognized for its focus on the research, development, and manufacturing of MDXX class molecules, including their flag product, MDMA. The company aims to address the global demand for clinical-grade MDMA and is committed to supporting clinical trials and commercial sales in select regions. Unique to PharmAla is its position as the sole source of clinical-grade MDMA supplied for patient treatments outside of clinical trials. Their research and development initiatives have already demonstrated proof-of-concept for several drug candidates, including ALA-002, the company's lead drug candidate.
Contact Information
For further inquiries, interested parties can contact:
Nicholas Kadysh
Chief Executive Officer
PharmAla Biotech Holdings Inc.
Email: press@PharmAla.ca
Phone: 1-855-444-6362
Website: www.PharmAla.ca
Frequently Asked Questions
What is PharmAla's recent agreement about?
PharmAla has reached an agreement to supply LaNeo MDMA for a clinical trial and, in return, will acquire valuable efficacy and safety data from the trial.
Who is PharmAla's CEO, and what did he say about the agreement?
Nicholas Kadysh is the CEO of PharmAla, and he stated that strong products can create unexpected opportunities, highlighting the importance of intellectual property in their agreements.
How will the agreement benefit researchers?
The agreement enables seamless access to LaNeo MDMA, along with comprehensive support from PharmAla to assist with clinical trial registrations and IRB approvals.
What financial move did PharmAla recently make?
PharmAla has settled $100,000 of debts by issuing common shares, demonstrating their strategic emphasis on financial health and innovation.
How can researchers get in touch with PharmAla for potential collaboration?
Researchers interested in collaborating can contact PharmAla through email at sales@pharmala.ca for inquiries related to data sharing and other opportunities.
